Trial Profile
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Bone metastases; Brain metastases; Carcinoma; Liver metastases; Thyroid cancer
- Focus Adverse reactions
- Acronyms LEN01T
- Sponsors Eisai Co Ltd
- 16 Jul 2020 Results (n=442) assessing safety and effectiveness of Lenvatinib, published in the Advances in Therapy
- 07 Jan 2020 Status changed from recruiting to completed.
- 10 Jul 2018 Planned End Date changed from 1 Mar 2026 to 1 Mar 2025.